Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81


Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.

Ghobadi A, Rettig MP, Holt MS, Ritchey JK, Kennerly K, Chendamarai E, Eissenberg L, DiPersio JF.

Blood. 2018 Jun 7;131(23):2594-2596. doi: 10.1182/blood-2017-10-811620. Epub 2018 Apr 25. No abstract available.


The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.

Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Noel TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE 3rd.

Oncotarget. 2016 Dec 6;7(49):81172-81186. doi: 10.18632/oncotarget.12791.


Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.

Al-Homsi AS, Goodyke A, McLane M, Abdel-Mageed S, Cole K, Muilenburg M, Feng Y.

Biol Blood Marrow Transplant. 2017 Feb;23(2):255-261. doi: 10.1016/j.bbmt.2016.11.015. Epub 2016 Nov 22.


Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.

Al-Homsi AS, Goodyke A, Cole K, Muilenburg M, McLane M, Abdel-Mageed S, Feng Y.

Exp Hematol. 2017 Apr;48:50-57. doi: 10.1016/j.exphem.2016.12.002. Epub 2016 Dec 19.


The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S.

Future Oncol. 2015;11(8):1153-68. doi: 10.2217/fon.15.9. Review.


Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG.

Lancet Oncol. 2014 Dec;15(13):1503-12. doi: 10.1016/S1470-2045(14)71125-8. Epub 2014 Nov 14.


Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.

Gupta N, Labotka R, Liu G, Hui AM, Venkatakrishnan K.

Invest New Drugs. 2016 Jun;34(3):338-46. doi: 10.1007/s10637-016-0346-7. Epub 2016 Apr 2.


A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Hanley MJ, Gupta N, Venkatakrishnan K, Bessudo A, Sharma S, O'Neil BH, Wang B, van de Velde H, Nemunaitis J.

J Clin Pharmacol. 2018 Jan;58(1):114-121. doi: 10.1002/jcph.987. Epub 2017 Aug 7.


Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.

Gupta N, Zhao Y, Hui AM, Esseltine DL, Venkatakrishnan K.

Br J Clin Pharmacol. 2015 May;79(5):789-800. doi: 10.1111/bcp.12542.


Mechanisms underlying hematopoietic stem cell mobilization induced by the CXC chemokine interleukin-8.

Pruijt JF, Willemze R, Fibbe WE.

Curr Opin Hematol. 1999 May;6(3):152-8.


The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.

Gupta N, Hanley MJ, Venkatakrishnan K, Wang B, Sharma S, Bessudo A, Hui AM, Nemunaitis J.

J Clin Pharmacol. 2016 Oct;56(10):1288-95. doi: 10.1002/jcph.719. Epub 2016 Mar 17.


Hematopoietic stem and progenitor cells are differentially mobilized depending on the duration of Flt3-ligand administration.

de Kruijf EJ, Hagoort H, Velders GA, Fibbe WE, van Pel M.

Haematologica. 2010 Jul;95(7):1061-7. doi: 10.3324/haematol.2009.016691. Epub 2010 Jan 15.


Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.

Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T, Venkatakrishnan K.

Target Oncol. 2017 Oct;12(5):643-654. doi: 10.1007/s11523-017-0524-3.


Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.

Gupta N, Huh Y, Hutmacher MM, Ottinger S, Hui AM, Venkatakrishnan K.

Cancer Chemother Pharmacol. 2015 Sep;76(3):507-16. doi: 10.1007/s00280-015-2815-7. Epub 2015 Jul 4.


An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.

Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P.

Onco Targets Ther. 2014 Sep 29;7:1793-800. doi: 10.2147/OTT.S49187. eCollection 2014. Review.


Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment.

Li H, Chen Z, Hu T, Wang L, Yu Y, Zhao Y, Sun W, Guan S, Pang JC, Woodfield SE, Liu Q, Yang J.

Sci Rep. 2016 Sep 30;6:34397. doi: 10.1038/srep34397.


Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.

Reese SR, Wilson NA, Huang G, Redfield RR 3rd, Zhong W, Djamali A.

Transplantation. 2015 Sep;99(9):1785-95. doi: 10.1097/TP.0000000000000736.


Mobilization of progenitor cells into peripheral blood by gamma-tocotrienol: a promising radiation countermeasure.

Ray S, Kulkarni SS, Chakraborty K, Pessu R, Hauer-Jensen M, Kumar KS, Ghosh SP.

Int Immunopharmacol. 2013 Mar;15(3):557-64. doi: 10.1016/j.intimp.2012.12.034. Epub 2013 Feb 12.


New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Richardson PG, Kumar S, Laubach JP, Paba-Prada C, Gupta N, Berg D, van de Velde H, Moreau P.

J Blood Med. 2017 Aug 22;8:107-121. doi: 10.2147/JBM.S102328. eCollection 2017. Review.

Supplemental Content

Support Center